Aktiesnakken — Marts 2012
-
ja bava får tæsk hver gang det ved vi
-
Patienter med prostatskræft i en tidlig fase lever længere, og sygdommen udvikler sig langsommere, hvis de bliver behandlet med Zytiga, der er Johnson & Johnsons lægemiddel mod prostatakræft. Det viser senfasestudier af midlet, skriver nyhedsbrevet Medwatch med henvisning til hjemmesiden The Street.
-
hvad skyldes panikken?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind